DTCFF - Defence Therapeutics to get US patent linked to vaccine technology

• Defence Therapeutics ( OTCPK:DTCFF ) said the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for its vaccine technology.
• The US patent application number 17/738,548 covers the use of components of Defence's proprietary Accum technology as a 'drop-in' enhancer ingredient to boost immunogenicity and performance of virtually any cell-based or protein subunit vaccine, the company added.
• The patent will help Defence to expand the development of novel vaccines and therapies in for cancer and infectious diseases, according to the company.
• "The ability of Defence's enhancer technology to greatly improve antigen loading on MHC molecules of antigen-presenting cells creates additional opportunities for improving upon existing vaccines, such as by reducing antigen dose, thereby lowering manufacturing costs and potentially diminishing patient adverse reactions," said Defence CEO and Director Sebastien Plouffe.

For further details see: